search
Back to results

Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism

Primary Purpose

Alcohol Dependence

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Naltrexone 50 Mg
Placebo
Sponsored by
Medical University of South Carolina
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alcohol Dependence focused on measuring Alcohol Dependence, Alcoholism, Naltrexone, Substance Abuse, Genetics

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria

  1. Age 18 70
  2. Subjects will meet criteria for primary alcohol dependence
  3. Consumes, on average, at least 5 standard drinks per day for men and 4 drinks per day for women in the 90 days pre-screening. Has at least 50% of days as heavy drinking days (as defined above).
  4. Able to maintain sobriety for four days (with or without the aid of alcohol detoxification medications) as determined by self report and breathalyzer measurements
  5. Able to read and understand questionnaires and informed consent
  6. Lives within approximately 50 miles of the study site

Exclusion Criteria

  1. Currently meets DSM IV criteria for any other psychoactive substance dependence disorder except nicotine dependence
  2. Any psychoactive substance abuse, except marijuana, nicotine, and cocaine, within the last 30 days as evidenced by subject report, collateral report, or urine drug screen. May meet cocaine abuse criteria, but not dependence, and also must have two sequential urines free of illicit substances
  3. Meets DSM IV criteria for current and active axis I disorders of major depression, panic disorder, obsessive compulsive disorder, post traumatic stress syndrome, bipolar affective disorder, schizophrenia, or any other psychotic disorder or organic mental disorder
  4. Meets DSM IV current criteria for dissociative disorder or eating disorders
  5. Has current suicidal ideation or homicidal ideation
  6. Need for maintenance or acute treatment with any psychoactive medication, except a stable dose (at least one month) of antidepressants
  7. Need for maintenance on anti-seizure medications (including topiramate and gabapentin)
  8. Use of disulfiram, acamprosate, or naltrexone in the last two weeks
  9. Clinically significant medical problems such as cardiovascular, renal, GI, or endocrine problem that would impair participation or limit medication ingestion
  10. Hepatocellular disease indicated by elevations of SGPT (ALT) and SGOT (AST) of at least 3.0 times normal at screening and/or after 5 days abstinence
  11. Sexually active female of child-bearing potential who is pregnant (by urine HCG), nursing, or who is not willing to use a reliable form of birth control
  12. Has current charges pending for a violent crime (not including DUI-related offenses)
  13. Does not have a stable living situation
  14. African American heritage due to low prevalence of Asp40 (also see Inclusion of Women and Minorities section)

Exclusion Criteria of fMRI Procedure

  1. Having metal objects in the body that are deemed unsafe in the MRI environment.
  2. Severe claustrophobia that cannot be managed with support and encouragement.
  3. Morbid obesity such that placement in the MRI scanner is impossible.
  4. History of significant head injury leading to unconsciousness.

Sites / Locations

  • Medical University of South Carolina, Center for Drug and Alcohol Programs
  • Medical University of South Carolin

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Placebo Comparator

Active Comparator

Placebo Comparator

Arm Label

A118G A/A with Naltrexone

A118G A/A with Placebo

A118G Any G with Naltrexone

A118G Any G with Placebo

Arm Description

Individuals with the OPRM1 genotype Asn40 are given naltrexone 50 mg after 2 days at 25 mg for 16 weeks with Medication Management 9 visits in 16 weeks

Individuals with the OPRM1 genotype Asn40 are given Placebo for 16 weeks with Medication Management in 16 weeks

Individuals with the OPRM1 genotype Any G (Asp) are given naltrexone 50 mg after 2 days of naltrexone 25 mg for 16 weeks with Medication Management 9 visits in 16 weeks

Individuals with the OPRM1 genotype Any G (Asp) are given 50 mg naltrexone after 2 days at 25 mg for 16 weeks with Medication Management 9 visits in 16 weeks

Outcomes

Primary Outcome Measures

Percent Heavy Drinking Days by mu Opioid Receptor Gene

Secondary Outcome Measures

Full Information

First Posted
June 11, 2009
Last Updated
June 12, 2018
Sponsor
Medical University of South Carolina
Collaborators
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
search

1. Study Identification

Unique Protocol Identification Number
NCT00920829
Brief Title
Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism
Official Title
Genetic and Brain Mechanisms of Naltrexone?s Treatment Efficacy for Alcoholism
Study Type
Interventional

2. Study Status

Record Verification Date
June 2018
Overall Recruitment Status
Completed
Study Start Date
June 2009 (undefined)
Primary Completion Date
December 2015 (Actual)
Study Completion Date
December 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medical University of South Carolina
Collaborators
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The overarching aim of this trial is to evaluate naltrexone's efficacy in light of genetic variation and brain response to alcohol cues utilizing a neuroimaging paradigm. This trial has four specific aims. First, this trial will evaluate whether the presence of the OPRM1 Asp40 allele substitution is associated with improved treatment response to naltrexone in treatment-seeking alcoholics. Second, it will evaluate whether there is a difference in the naltrexone dampening of the alcohol cue-induced brain activation dependent on OPRM1 genotype. Third, it will explore whether alcohol cue-induced brain activation dampening by naltrexone might be a mediating factor in the treatment effects of naltrexone, the OPRM1 gene, or their interaction that might be observed in the first aim. Finally, this trial will evaluate the effect of medication compliance, or adverse effects, on the observed medication by genotype treatment response. A secondary aim will measure medication compliance and side effects based on OPRM1 genotype.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alcohol Dependence
Keywords
Alcohol Dependence, Alcoholism, Naltrexone, Substance Abuse, Genetics

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Factorial Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
358 (Actual)

8. Arms, Groups, and Interventions

Arm Title
A118G A/A with Naltrexone
Arm Type
Active Comparator
Arm Description
Individuals with the OPRM1 genotype Asn40 are given naltrexone 50 mg after 2 days at 25 mg for 16 weeks with Medication Management 9 visits in 16 weeks
Arm Title
A118G A/A with Placebo
Arm Type
Placebo Comparator
Arm Description
Individuals with the OPRM1 genotype Asn40 are given Placebo for 16 weeks with Medication Management in 16 weeks
Arm Title
A118G Any G with Naltrexone
Arm Type
Active Comparator
Arm Description
Individuals with the OPRM1 genotype Any G (Asp) are given naltrexone 50 mg after 2 days of naltrexone 25 mg for 16 weeks with Medication Management 9 visits in 16 weeks
Arm Title
A118G Any G with Placebo
Arm Type
Placebo Comparator
Arm Description
Individuals with the OPRM1 genotype Any G (Asp) are given 50 mg naltrexone after 2 days at 25 mg for 16 weeks with Medication Management 9 visits in 16 weeks
Intervention Type
Drug
Intervention Name(s)
Naltrexone 50 Mg
Intervention Description
Naltrexone 25 or 50 mg per titration schedule
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
placebo
Primary Outcome Measure Information:
Title
Percent Heavy Drinking Days by mu Opioid Receptor Gene
Time Frame
Time Line Follow-Back drinking collected at each of 9 visits (weeks 1, 2, 3, 4, 6, 8, 10, 12 and 16)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Age 18 70 Subjects will meet criteria for primary alcohol dependence Consumes, on average, at least 5 standard drinks per day for men and 4 drinks per day for women in the 90 days pre-screening. Has at least 50% of days as heavy drinking days (as defined above). Able to maintain sobriety for four days (with or without the aid of alcohol detoxification medications) as determined by self report and breathalyzer measurements Able to read and understand questionnaires and informed consent Lives within approximately 50 miles of the study site Exclusion Criteria Currently meets DSM IV criteria for any other psychoactive substance dependence disorder except nicotine dependence Any psychoactive substance abuse, except marijuana, nicotine, and cocaine, within the last 30 days as evidenced by subject report, collateral report, or urine drug screen. May meet cocaine abuse criteria, but not dependence, and also must have two sequential urines free of illicit substances Meets DSM IV criteria for current and active axis I disorders of major depression, panic disorder, obsessive compulsive disorder, post traumatic stress syndrome, bipolar affective disorder, schizophrenia, or any other psychotic disorder or organic mental disorder Meets DSM IV current criteria for dissociative disorder or eating disorders Has current suicidal ideation or homicidal ideation Need for maintenance or acute treatment with any psychoactive medication, except a stable dose (at least one month) of antidepressants Need for maintenance on anti-seizure medications (including topiramate and gabapentin) Use of disulfiram, acamprosate, or naltrexone in the last two weeks Clinically significant medical problems such as cardiovascular, renal, GI, or endocrine problem that would impair participation or limit medication ingestion Hepatocellular disease indicated by elevations of SGPT (ALT) and SGOT (AST) of at least 3.0 times normal at screening and/or after 5 days abstinence Sexually active female of child-bearing potential who is pregnant (by urine HCG), nursing, or who is not willing to use a reliable form of birth control Has current charges pending for a violent crime (not including DUI-related offenses) Does not have a stable living situation African American heritage due to low prevalence of Asp40 (also see Inclusion of Women and Minorities section) Exclusion Criteria of fMRI Procedure Having metal objects in the body that are deemed unsafe in the MRI environment. Severe claustrophobia that cannot be managed with support and encouragement. Morbid obesity such that placement in the MRI scanner is impossible. History of significant head injury leading to unconsciousness.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Raymond F Anton, MD
Organizational Affiliation
Medical University of South Carolina
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical University of South Carolina, Center for Drug and Alcohol Programs
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
Facility Name
Medical University of South Carolin
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
28409564
Citation
Schacht JP, Randall PK, Latham PK, Voronin KE, Book SW, Myrick H, Anton RF. Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status. Neuropsychopharmacology. 2017 Dec;42(13):2640-2653. doi: 10.1038/npp.2017.74. Epub 2017 Apr 14. Erratum In: Neuropsychopharmacology. 2017 Dec;42(13):2654.
Results Reference
result
Links:
URL
https://www.ncbi.nlm.nih.gov/pubmed/28409564
Description
Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status.

Learn more about this trial

Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism

We'll reach out to this number within 24 hrs